5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment
In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
Shanghai Pilots: Leading Value-Based and Risk-Sharing Reimbursement for Medical Consumables in China
Shanghai utilizes value-based pricing negotiations and performance-linked payments for medical consumable reimbursements, providing insights into the future direction of high-value medical consumable reimbursement under China's basic medical insurance.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations
These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
Pudong Drug Pricing Pilot
#1 Pudong reform pilot permits new drug launch pricing comparable to international markets.
On January 22nd, a joint announcement was
Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation
Although NRDL negotiation involves multiple aspects, at its core, the most fundamental issue is the fair pricing of innovative pharmaceuticals.
